These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21322311)

  • 1. [Development of animal models, and drug discovery for schizophrenia based on the glutamate hypothesis].
    Nabeshima T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):195. PubMed ID: 21322311
    [No Abstract]   [Full Text] [Related]  

  • 2. [Development of psychotropic agents for schizophrenia based on the glutamate hypothesis].
    Nishikawa T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):193. PubMed ID: 21322312
    [No Abstract]   [Full Text] [Related]  

  • 3. Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis.
    Enomoto T; Noda Y; Nabeshima T
    Methods Find Exp Clin Pharmacol; 2007 May; 29(4):291-301. PubMed ID: 17609743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamate as a therapeutic target in psychiatric disorders.
    Javitt DC
    Mol Psychiatry; 2004 Nov; 9(11):984-97, 979. PubMed ID: 15278097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine.
    Nabeshima T; Mouri A; Murai R; Noda Y
    Ann N Y Acad Sci; 2006 Nov; 1086():160-8. PubMed ID: 17185514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of a novel pharmacotherapy targeted at the N-methyl-D-aspartate receptor-D-serine system for schizophrenia].
    Nishikawa T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):201-6. PubMed ID: 21226316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment.
    Mouri A; Noda Y; Enomoto T; Nabeshima T
    Neurochem Int; 2007; 51(2-4):173-84. PubMed ID: 17669558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The N-methyl-D-aspartate receptor and schizophrenia.
    Strous RD; Javitt DC
    Isr J Med Sci; 1996 May; 32(5):275-81. PubMed ID: 8641863
    [No Abstract]   [Full Text] [Related]  

  • 9. [Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].
    Hashimoto K; Iyo M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2002 Feb; 22(1):3-13. PubMed ID: 11917507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of the glutamate, GABA, and dopamine systems in relation to NRH-induced neurotoxicity.
    Benes FM
    Biol Psychiatry; 1995 Dec; 38(12):783-7. PubMed ID: 8750035
    [No Abstract]   [Full Text] [Related]  

  • 11. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Receptor antagonist of NMDA and animal models of schizophrenia].
    Bian SZ; Zhang J; Liu WL; Sun ZH; Gu ZL; Jiang XG
    Fa Yi Xue Za Zhi; 2009 Dec; 25(6):443-6. PubMed ID: 20225623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Glycine therapy of schizophrenia; its rationale and a review of clinical trials].
    Semba J
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Jun; 18(3):71-80. PubMed ID: 9800198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
    Pietraszek M
    Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neuropsychopharmacological study on an animal model for negative symptom of schizophrenia induced by repeated phencyclidine treatment].
    Noda Y; Nabeshima T
    Yakugaku Zasshi; 2000 Aug; 120(8):677-82. PubMed ID: 10946617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The phencyclidine-N-methyl-D-aspartate theory of schizophrenia: clinical applications].
    Heresco-Levy U; Elman I; Javitt D
    Harefuah; 1994 May; 126(10):598-601. PubMed ID: 8034251
    [No Abstract]   [Full Text] [Related]  

  • 17. Anabasine, a selective nicotinic acetylcholine receptor agonist, antagonizes MK-801-elicited mouse popping behavior, an animal model of schizophrenia.
    Mastropaolo J; Rosse RB; Deutsch SI
    Behav Brain Res; 2004 Aug; 153(2):419-22. PubMed ID: 15265637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Schizophrenia and glutamate transport systems].
    Nishikawa T
    Seishin Shinkeigaku Zasshi; 2009; 111(7):859-67. PubMed ID: 19999298
    [No Abstract]   [Full Text] [Related]  

  • 19. N-methyl-D-aspartate antagonists as drug models of schizophrenia: a surprising link to tobacco smoking.
    Domino EF; Mirzoyan D; Tsukada H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Aug; 28(5):801-11. PubMed ID: 15363604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.
    Laruelle M; Frankle WG; Narendran R; Kegeles LS; Abi-Dargham A
    Clin Ther; 2005; 27 Suppl A():S16-24. PubMed ID: 16198197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.